Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives

Abstract

Abstract Nanoparticles have transformed drug delivery, imaging, vaccination, and precision therapeutics, but their clinical translation remains constrained by safety profiles that are inseparable from material design, biological identity, host factors, and manufacturing. This review critically evaluates recent progress, persistent limitations, and priority objectives for safer nanomedicine. Unlike reviews organized primarily by material class or isolated toxicology endpoints, we integrate physicochemical determinants, protein corona formation, immune recognition, organ disposition, preclinical models, chemistry-manufacturing-controls (CMC), regulatory expectations, disease context, and patient heterogeneity into a translational safety-by-design framework. We distinguish clinically established risk-mitigation strategies from emerging approaches and examine why apparently favorable preclinical performance may fail to predict human safety. Particular attention is given to complement activation, repeat-dose immunogenicity, long-term retention, blood-brain barrier delivery, oncology and inflammatory disease, assay interference, quantitative biodistribution, and scale-up. Artificial intelligence, physiologically based pharmacokinetic modeling, multi-omics, organ-on-chip systems, imaging, and digital-twin concepts are evaluated as emerging tools for predictive safety, while their present validation limitations are emphasized. Overall, the evidence supports early integration of efficacy, mechanistic toxicology, CMC, and patient-specific risk rather than downstream safety testing alone. Harmonized characterization, clinically relevant models, long-term fate studies, and lifecycle surveillance remain central priorities for the next generation of nanomedicines.